Roth Capital analyst Joseph Pantginis maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a price target of $3.00, following the company’s third-quarter …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $4 price …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on ImmunoCellular Therapeutics (OTCBB:IMUC) with a $3 price …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a $3 price target, …
In a research note published August 8th, Roth Capital analyst Joseph Pantginis maintained a Buy rating on ImmunoCellular Therapeutics (IMUC) with a $3 …